NLS Pharmaceutics AG has announced a significant update to its merger and reorganization plans with Kadimastem Ltd. The Seventh Amendment to the Agreement of Merger and Plan of Reorganization was executed on August 29, 2025. This amendment involves NLS Pharmaceutics Ltd., NLS Pharmaceuticals (Israel) Ltd., and Kadimastem Ltd., a publicly traded Israeli company. The amendment was signed by key representatives, including Alexander C. Zwyer, CEO of NLS Pharmaceutics Ltd., and Ronen Twito, CEO of Kadimastem Ltd. This update marks a continued collaboration between the companies, as they work towards completing the merger process.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-082550), on August 29, 2025, and is solely responsible for the information contained therein.